# FDA, Duke-Margolis workshop to examine evidence standards for rare diseases — retained record

> Retained news record from news:seeking-alpha.

Canonical: https://highsignal.app/data/records/199e34584b973639

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:seeking-alpha)  published 2026-09-20 18:57 ingested 2026-09-21 02:47

[original source ↗](https://seekingalpha.com/news/4644591-fda-duke-margolis-workshop-to-examine-evidence-standards-for-rare-diseases?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news)

## retained text



```
The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease development: how to generate reliable evidence when the number of available patients
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Sep 20, 2026, 2:57 PM ETState Street SPDR S&P Biotech ETF (XBI), SRPT Stock, VRTX Stock, REGN Stock, ALNY Stock, JAZZ Stock, INCY Stock, ROIV Stock, INSM Stock, RPRX Stock, SMMT Stock, CAPR Stock, SLN Stock, SLS Stock, MESO Stock, TLX Stock, IBRX StockBy: Rob Williams, SA News Editor3 Comments
```



document fetched 2026-09-21 02:47 · canonical https://seekingalpha.com/news/4644591-fda-duke-margolis-workshop-to-examine-evidence-standards-for-rare-diseases?feed_item_type=news